Lower urinary tract symptoms in men

Benign prostatic hyperplasia (BPH) is a highly prevalent and costly condition that affects older men worldwide. Many affected men develop lower urinary tract symptoms, which can have a negative impact on their quality of life. In the past, transurethral resection of the prostate (TURP) was the mainstay of treatment. However, several efficacious drug treatments have been developed, which have transformed BPH from an acute surgical entity to a chronic medical condition. Specifically, multiple clinical trials have shown that α adrenoceptor antagonists can significantly ameliorate lower urinary tract symptoms. Moreover, 5α reductase inhibitors, alone or combined with an α adrenoceptor antagonist, can reverse the natural course of BPH, reducing the risk of urinary retention and the need for surgical intervention. Newer medical regimens including the use of antimuscarinic agents or phosphodiesterase type 5 inhibitors, have shown promise in men with predominantly storage symptoms and concomitant erectile dysfunction, respectively. For men who do not adequately respond to conservative measures or pharmacotherapy, minimally invasive surgical techniques (such as transurethral needle ablation, microwave thermotherapy, and prostatic urethral lift) may be of benefit, although they lack the durability of TURP. A variety of laser procedures have also been introduced, whose improved hemostatic properties abrogate many of the complications associated with traditional surgery.

[1]  P. Abrams,et al.  Lower urinary tract symptom: still too much focus on the prostate? , 2014, Current opinion in urology.

[2]  S. Maclennan,et al.  Systematic review and meta‐analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP) , 2014, BJU international.

[3]  John T. Wei,et al.  The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. , 2013, The Journal of urology.

[4]  J. Macoska,et al.  Promising Molecular Targets and Biomarkers for Male BPH and LUTS , 2013, Current Urology Reports.

[5]  C. Roehrborn,et al.  Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. , 2013, European urology.

[6]  J. Mckinlay,et al.  Intake of caffeinated, carbonated, or citrus beverage types and development of lower urinary tract symptoms in men and women. , 2013, American journal of epidemiology.

[7]  H. Woo,et al.  Photoselective vaporization with the green light laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: a systematic review and meta‐analysis , 2013, BJU international.

[8]  M. Marberger,et al.  A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. , 2013, European urology.

[9]  T. Morita,et al.  Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia , 2012, BMC Urology.

[10]  J. Hollingsworth,et al.  Prostatic fibrosis is associated with lower urinary tract symptoms. , 2012, The Journal of urology.

[11]  T. Tammela,et al.  [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe]. , 2012, Urologiia.

[12]  Toshimitsu Kobayashi,et al.  New classification for men with lower urinary tract symptoms: cluster analysis using the International Prostate Symptom Score , 2012, BJU international.

[13]  T. Wilt,et al.  Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review , 2012, BJU international.

[14]  B. Challacombe,et al.  Is there a link between BPH and prostate cancer? , 2012, The Practitioner.

[15]  G. Skipka,et al.  Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence (non‐inferiority) , 2012, BJU international.

[16]  C. Roehrborn,et al.  Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. , 2011, JAMA.

[17]  T. Tammela,et al.  Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS) , 2011, BJU international.

[18]  Thomas A. Wynn,et al.  Integrating mechanisms of pulmonary fibrosis , 2011, The Journal of experimental medicine.

[19]  C. Roehrborn,et al.  Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) , 2011, BJU international.

[20]  John T. Wei,et al.  Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. , 2011, Urology.

[21]  C. Roehrborn,et al.  Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action , 2011, Neurourology and urodynamics.

[22]  O. Ogawa,et al.  Efficacy of nondrug lifestyle measures for the treatment of nocturia. , 2010, The Journal of urology.

[23]  A. Vannacci,et al.  Acute liver damage due to Serenoa repens: a case report. , 2010, British journal of clinical pharmacology.

[24]  D. Tindall,et al.  Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[25]  I. Pearce,et al.  Transurethral resection of the prostate syndrome: almost gone but not forgotten. , 2009, Journal of endourology.

[26]  John T. Wei,et al.  Differences in initial benign prostatic hyperplasia management between primary care physicians and urologists. , 2009, The Journal of urology.

[27]  Andrea Tubaro,et al.  The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study , 2009, BJU international.

[28]  J. K. Parsons,et al.  Lower urinary tract symptoms increase the risk of falls in older men , 2009, BJU international.

[29]  M. Irigoyen,et al.  A Brief Review of Chronic Exercise Intervention to Prevent Autonomic Nervous System Changes During the Aging Process , 2009, Clinics.

[30]  P. Barnes,et al.  Complementary and alternative medicine use among adults and children: United States, 2007. , 2008, National health statistics reports.

[31]  O. Baylis,et al.  Alpha antagonists and intraoperative floppy iris syndrome: A spectrum , 2008, Clinical ophthalmology.

[32]  A. Grant,et al.  Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials , 2008, BMJ : British Medical Journal.

[33]  M. Melekos,et al.  Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. , 2008, European urology.

[34]  M. Moyad,et al.  Educating patients about lifestyle modifications for prostate health. , 2008, The American journal of medicine.

[35]  Timothy J Wilt,et al.  Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. , 2008, The Journal of urology.

[36]  S. Masket,et al.  Clinical experience with intraoperative floppy‐iris syndrome: Results of the 2008 ASCRS member survey , 2008, Journal of cataract and refractive surgery.

[37]  D. Dubey,et al.  Thulium laser versus standard transurethral resection of the prostate: A randomized prospective trial , 2008, Indian journal of urology : IJU : journal of the Urological Society of India.

[38]  Alexander Bachmann,et al.  Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. , 2008, The Journal of urology.

[39]  T. Fenter,et al.  Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. , 2008, The American journal of managed care.

[40]  H. Bream-Rouwenhorst,et al.  Intraoperative Floppy Iris Syndrome Associated with α1-Adrenergic Receptor Antagonists , 2008, The Annals of pharmacotherapy.

[41]  B. Schurch,et al.  Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. , 2008, European urology.

[42]  M. Kattan,et al.  Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[43]  C. Roehrborn Self management for men with lower urinary tract symptoms: randomised controlled trial , 2007, BMJ : British Medical Journal.

[44]  C. Roehrborn,et al.  Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. , 2006, The Journal of urology.

[45]  C. Roehrborn,et al.  Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. , 2006, JAMA.

[46]  R. Packard,et al.  Intraoperative floppy-iris syndrome associated with tamsulosin. , 2006, Journal of cataract and refractive surgery.

[47]  C. Chapple,et al.  Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. , 2006, European urology.

[48]  P. Abrams,et al.  Noninvasive methods of diagnosing bladder outlet obstruction in men. Part 1: Nonurodynamic approach. , 2006, The Journal of urology.

[49]  L. Ferrucci,et al.  Metabolic factors associated with benign prostatic hyperplasia. , 2006, The Journal of clinical endocrinology and metabolism.

[50]  C. Bouza,et al.  Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia , 2006, BMC urology.

[51]  I. Jibrin,et al.  Saw palmetto-induced pancreatitis. , 2006, Southern medical journal.

[52]  M. Chancellor,et al.  Intraprostatic injection of botulinum toxin type- A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs , 2006, BMC urology.

[53]  C. Roehrborn,et al.  A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. , 2006, European urology.

[54]  L. Vatten,et al.  The prevalence and correlates of urinary tract symptoms in Norwegian men: The HUNT Study , 2005, BJU international.

[55]  R. Rosen,et al.  Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). , 2005, European urology.

[56]  John T. Wei,et al.  Urologic diseases in America project: benign prostatic hyperplasia. , 2005, The Journal of urology.

[57]  M. Elhilali,et al.  Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction , 2005, BJU international.

[58]  N. Fried,et al.  High-power thulium fiber laser ablation of urinary tissues at 1.94 microm. , 2005, Journal of endourology.

[59]  T. Wilt,et al.  Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects , 2004, BJU international.

[60]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[61]  M. Wyllie,et al.  Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies , 2003, BJU international.

[62]  A. Bentivoglio,et al.  Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. , 2003, Urology.

[63]  Michael M Lieber,et al.  The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.

[64]  P. Boyle,et al.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.

[65]  Jie Deng,et al.  Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. , 2002, The Journal of urology.

[66]  M. Barry,et al.  Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. , 2001, Journal of clinical epidemiology.

[67]  B. Högstedt,et al.  Hyperinsulinaemia as a Risk Factor for Developing Benign Prostatic Hyperplasia , 2001, European Urology.

[68]  G. Bales,et al.  Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. , 1999, Urology.

[69]  T. Wilt,et al.  Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. , 1998, JAMA.

[70]  A. Tewari,et al.  A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. , 1998, The Journal of urology.

[71]  R. Schmidt,et al.  Botox‐induced prostatic involution , 1998, The Prostate.

[72]  D M Barrett,et al.  High-power potassium titanyl phosphate laser vaporization prostatectomy. , 1998, Mayo Clinic proceedings.

[73]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. , 1998, The New England journal of medicine.

[74]  H. Lepor Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. , 1998, Urology.

[75]  R C Bruskewitz,et al.  Recent developments in the surgical management of benign prostatic hyperplasia. , 1998, Urology.

[76]  P. Gilling,et al.  The results of holmium laser resection of the prostate. , 1998, British journal of urology.

[77]  P. Gilling,et al.  The use of the holmium laser in the treatment of benign prostatic hyperplasia. , 1996, Journal of endourology.

[78]  H. Lepor,et al.  The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. , 1996, The New England journal of medicine.

[79]  M. Barry,et al.  Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? , 1995, The Journal of urology.

[80]  W. Hop,et al.  Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. , 1995, Urology.

[81]  C. Fowler,et al.  A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. , 1995, Urology.

[82]  J. Kabalin,et al.  A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. , 1995, Urology.

[83]  D. Gillatt,et al.  What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker. , 1995, British journal of urology.

[84]  E. Rimm,et al.  Obesity and benign prostatic hyperplasia. , 1994, American journal of epidemiology.

[85]  F. Montorsi,et al.  A modified prostatic UroLume Wallstent for healthy patients with symptomatic benign prostatic hyperplasia: a European Multicenter Study. , 1994, Urology.

[86]  D. Peehl,et al.  The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[87]  C. C. Chen,et al.  Natural history of prostatism: urinary flow rates in a community-based study. , 1993, The Journal of urology.

[88]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[89]  J. Oesterling,et al.  The prevalence of prostatism: a population-based survey of urinary symptoms. , 1993, The Journal of urology.

[90]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[91]  E. Shapiro Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia. , 1990, The Urologic clinics of North America.

[92]  C. West,et al.  Maximum and average urine flow rates in normal male and female populations--the Liverpool nomograms. , 1989, British journal of urology.

[93]  K. Kurth,et al.  Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on 6 cases. , 1987, European urology.

[94]  P. Walsh,et al.  The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.

[95]  S. Meretyk,et al.  A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. , 1978, British journal of urology.

[96]  S. Raz,et al.  Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. , 1975, British journal of urology.

[97]  J. W. White I. The Question of Castration for Enlarged Prostate. , 1896, Annals of surgery.

[98]  A. T. Cabot II. The Question of Castration for Enlarged Prostate. , 1896, Annals of surgery.

[99]  C. Roehrborn,et al.  A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia , 2012 .

[100]  M. Emberton,et al.  Guidelines on the Treatment of Non-neurogenic Male LUTS , 2011 .

[101]  G. Vannelli,et al.  Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. , 2010, The journal of sexual medicine.

[102]  C. Roehrborn,et al.  The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. , 2010, European urology.

[103]  H. Lepor,et al.  The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia. , 2008, Reviews in urology.

[104]  T. Wilt,et al.  Microwave thermotherapy for benign prostatic hyperplasia. , 2007, The Cochrane database of systematic reviews.

[105]  J. Dimitrakov Saw palmetto for benign prostatic hyperplasia. , 2006, The New England journal of medicine.

[106]  V. Nitti Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. , 2005, Reviews in urology.

[107]  M. Pinzani Liver fibrosis , 2004, Springer Seminars in Immunopathology.

[108]  P. Boyle,et al.  Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. , 2003, Urology.

[109]  S. Kaplan Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. , 2002, The Journal of urology.

[110]  T. Wilt,et al.  Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. , 2002, The Journal of urology.

[111]  D. Porru,et al.  Evaluation of morbidity of multi‐channel pressure‐flow studies , 1999, Neurourology and urodynamics.

[112]  P. Abrams LUTS, BPH, BPE, BPO: A Plea for the Logical Use of Correct Terms. , 1999, Reviews in urology.

[113]  C C Schulman,et al.  Transurethral needle ablation (TUNA): safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. , 1993, European urology.

[114]  P. Walsh,et al.  Clinical and experimental studies of benign prostatic hyperplasia. , 1990, The Urologic clinics of North America.

[115]  D. S. Coffey,et al.  Etiology and disease process of benign prostatic hyperplasia , 1989, The Prostate. Supplement.

[116]  K. Fabian [The intra-prostatic "partial catheter" (urological spiral) (author's transl)]. , 1980, Der Urologe. Ausg. A.